Joseph Gallant, PhD

Joe obtained his PhD in Molecular and Cellular Pharmacology from the University of Wisconsin in 2023. He completed his training at Wisconsin in the lab of Dr. Aaron LeBeau, PhD, focusing on the development of single domain antibodies as novel theranostic platform technologies for metastatic prostate cancer. 

His research interests surround the development and engineering of non-canonical antibodies derived from species such as sharks and llamas. Joseph joined the Pravetoni lab May 2024 and is currently developing non-canonical antibodies for the treatment of overdose related to ultra-potent synthetic opioids. In his free time, Joe enjoys being a cat dad, searching for classic vinyls, and finding new coffee shops.